Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Karuna Therapeutics Inc
(NQ:
KRTX
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, Mar 15, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Karuna Therapeutics Inc
< Previous
1
2
3
Next >
Karuna Therapeutics to Present at Upcoming Investor Conferences
May 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Announce First Quarter 2023 Financial Results and Provide General Business Update on Thursday, May 4, 2023
April 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
March 24, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the Stifel 2023 CNS Days
March 23, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
March 21, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
March 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Result and Provides General Business Updates
February 23, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the SVB Securities Global Biopharma Conference
February 09, 2023
From
Karuna
Via
Business Wire
Karuna Therapeutics Announces Exclusive Global License Agreement for Goldfinch Bio’s Investigational TRPC4/5 Product Candidates
February 02, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Appoints William P. Kane as Chief Commercial Officer
January 31, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
January 03, 2023
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Appoints Bill Meury as President and Chief Executive Officer
December 06, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Reports Third Quarter 2022 Financial Results and Provides General Business Updates
November 03, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Present at the Jefferies 2022 London Healthcare Conference
November 01, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics
October 11, 2022
From
PsychoGenics Inc.
Via
Business Wire
Karuna Therapeutics to Present Data from the Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia at the 35th European College of Neuropsychopharmacology (ECNP) Congress
October 06, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Mainz Biomed (MYNZ) nominates two notable leaders in key areas of the diagnostics field to its Board of Directors
September 29, 2022
Via
AB Newswire
Karuna Therapeutics to Present at Upcoming Investor Conferences
September 01, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares
August 12, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
August 09, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Proposed Public Offering of Common Stock
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics (NASDAQ: KRTX) Reports Positive Primary and Secondary Endpoint Results from Phase 3 EMERGENT-2 Clinical Trial of KarXT for Treating Schizophrenia
August 08, 2022
Karuna Therapeutics, Inc. (NASDAQ: KRTX) is engaged as a clinical-stage biopharmaceutical company that is focused on the research and development
Via
Spotlight Growth
Karuna Therapeutics Reports Second Quarter 2022 Financial Results and Provides General Business Updates
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-2 Trial of KarXT in Schizophrenia
August 08, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm
June 16, 2022
From
The Schall Law Firm
Via
Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
June 06, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer’s Disease
May 18, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update
May 05, 2022
From
Karuna Therapeutics, Inc.
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.